Earnings release
Page 1
editas MEDICINE Exhibit 99.1 Editas Medicine Announces Second Quarter 2026 Results and Business Updates EDIT - 401 on track for CTN submission this month with data update in Q1 2027 Recently presented pre - clinical data demonstrating ~ 90 % or greater mean reduction in multiple atherogenic lipoproteins , including LDL - C , Lp ( a ) and ApoB with EDIT - 401 in non - human primates Recent financing strengthens Company's capital position , supporting continued advancement of EDIT - 401 program , with cash runway into the second half of 2028 CAMBRIDGE , Mass . , August 5 , 2026 – Editas Medicine , Inc. ( Nasdaq : EDIT ) , a pioneering gene editing company focused on developing transformative medicines for serious diseases , today reported financial results for the second quarter 2026 and provided business updates . " During the second quarter , we continued preclinical work to support advancing EDIT - 401 into a single ascending dose , open - label Phase 1/2 study , ” said Gilmore O'Neill , M.B. , M.M.Sc. , President and Chief Executive Officer of Editas Medicine . “ We also presented new preclinical data demonstrating the ability of a single dose of EDIT - 401 to achieve rapid and significant reductions in multiple atherogenic lipoproteins in non - human primates along with a promising preclinical safety profile , reinforcing EDIT - 401's potential as a best - in - class , one - time treatment for hyperlipidemia . In addition , with our recent equity financing , we are well capitalized to drive the clinical development of EDIT - 401 through key value - creating milestones . We look forward to our continued progress and expect to provide a data update in the first quarter of 2027. " EDIT - 401 • • Editas presented new EDIT - 401 preclinical data at the 94th European Atherosclerosis Society ( EAS ) Congress , the 2026 Annual Meeting of the American Society of Gene and Cell Therapy ( ASGCT ) , and TIDES USA 2026 : Oligonucleotide and Peptide Therapeutics Conference , including : ° ° A single dose of EDIT - 401 achieved ~ 90 percent or greater mean reductions in LDL cholesterol ( LDL - C ) , lipoprotein ( a ) ( Lp ( a ) ) , and apolipoprotein B ( ApoB ) , with rapid and dose - dependent effect , in non - human primates ( NHPs ) . LDL - C mean reduction of ≥90 % with a single dose of EDIT - 401 in NHPs was durable through ~ 6 months . No adverse clinical observations were observed in NHPs at a single dose of 1.5mg / kg . Editas is on track to submit a Clinical Trial Notification ( CTN ) in Australia this month and continues to progress towards initiating a Phase 1/2 clinical trial of EDIT - 401 in patients with Heterozygous Familial Hypercholesterolemia ( HeFH ) . ° ° The Phase 1/2 study will evaluate the safety , tolerability , and efficacy of a single dose of EDIT - 401 . The trial is designed in two parts . Part 1 of the study is a single ascending dose , open - label trial design . Editas has selected four clinical trial sites across Australia and New Zealand . The Company expects to report a data update in the first quarter of 2027 . Editas plans to complete enrollment in Part 1 , the dose - finding portion of the Phase 1/2 trial of EDIT - 401 , with topline data results available in 2027 .
Page 2
Corporate & Business Development Updates • In May, Editas completed a public offering of common stock and accompanying common stock warrants. The aggregate gross proceeds from the offering were $125.0 million, before deducting underwritingdiscounts and commissions and offering expenses. In addition, if all common stock warrants are exercisedat their exercise price, the Company would receive additional gross proceeds from the offering ofapproximately $194.4 million before deducting underwriting discounts and commissions and offeringexpenses.• Editas announced the appointment of Patrick T. Ellinor, M.D., Ph.D. to its Board of Directors. Dr. Ellinor isa recognized leader in cardiovascular medicine and human genetics and brings extensive experiencespanning scientific innovation, therapeutic discovery, and clinical leadership to Editas. Second Quarter 2026 Financial ResultsCash and cash equivalents as of June 30, 2026, were $211.6 million compared to $146.6 million as ofDecember 31, 2025. The Company expects that the existing cash and cash equivalents will enable the Company tofund its operating expenses and capital expenditure requirements into the second half of 2028. Second Quarter 2026 • For the three months ended June 30, 2026, net loss attributable to common stockholders was $18.2 million, or$0.15 per share, compared to net loss of $53.2 million, or $0.63 per share, for the same period in 2025. • Collaboration and other research and development revenues increased to $11.9 million for the three monthsended June 30, 2026, compared to $3.6 million for the same period in 2025. The increase was primarilyattributable to the recognition of deferred revenue related to the expiration certain rights to opt-in to additionalresearch programs under its collaboration with BMS. • Research and development expenses increased by $4.0 million to $20.2 million for the three months ended June30, 2026, compared to $16.2 million for the same period in 2025. The decrease is primarily related to increasedexternal expenses for ongoing research and preclinical efforts for EDIT-401. • General and administrative expenses decreased by $1.3 million to $11.6 million for the three months endedJune 30, 2026 compared to $12.9 million for the same period in 2025. The decrease is primarily attributable to areduction in employee-related expenses, as well as reduced professional services, in connection with thereduction in headcount (the “Reduction”) and discontinuation of the clinical development of the Company’sreni-cel program (the “Discontinuation”) initiated in December 2024 and ongoing throughout 2025. • Restructuring and impairment charges decreased by $27.4 million to a $1.3 million benefit for the three monthsended June 30, 2026 compared to $26.1 million for the same period in 2025. The decrease is primarilyattributable to favorable adjustments to prior estimated costs for contracts associated with the Discontinuationupon finalization of contract costs. About Heterozygous Familial Hypercholesterolemia (HeFH)Heterozygous Familial Hypercholesterolemia (HeFH) is an inherited genetic disorder that leads to significantlyelevated LDL ‑ cholesterol levels from an early age. Individuals with HeFH are at high risk of heart disease, heartattack, or stroke if the condition is not identified and treated early. An estimated 1.2 million people in the UnitedStates are living with HeFH, though many remain undiagnosed. Elevated LDL-C, also known as hyperlipidemia, isa highly prevalent disease affecting over 70 million patients in the United States alone. Substantial unmet needexists across multiple at-risk segments of patients with hyperlipidemia, including the HeFH population.
Page 3
About Editas MedicineAs a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of theCRISPR genome editing systems into a robust pipeline of transformative in vivo medicines for people living withserious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercializedurable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusivelicensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estatesfor human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com. Forward-Looking StatementsThis press release contains forward-looking statements and information within the meaning of The PrivateSecurities Litigation Reform Act of 1995. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ ‘‘estimate,’’‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ ‘‘would,’’ and similarexpressions are intended to identify forward-looking statements, although not all forward-looking statementscontain these identifying words. Forward-looking statements in this press release include statements regarding theinitiation, timing, progress and results of the Company’s preclinical studies and planned clinical trials, including theCompany’s expectation to complete enrolling the dose-finding portion of the planned Phase 1/2 clinical trial ofEDIT-401 with topline data results available in 2027; the timing for the Company’s receipt and presentation of datafrom its preclinical and planned clinical studies, including providing a data update on EDIT-401 in the first quarterof 2027; the potential of, and expectations for, EDIT-401; the timing or likelihood of regulatory submissions andapprovals, including submission of a CTN in Australia this month; and the Company’s expectations regarding itscash runway. The Company may not actually achieve the plans, intentions, or expectations disclosed in theseforward-looking statements, and you should not place undue reliance on these forward-looking statements. Actualresults or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including: uncertainties inherent in the initiation, timing,progress, and results of preclinical studies and clinical trials; uncertainty regarding availability and timing of resultsfrom preclinical studies and clinical trials; uncertainties relating to planned regulatory submissions to initiateclinical trials, including that results of preclinical studies will warrant such submissions or that regulatory agenciesmay require additional preclinical studies, that regulatory submissions shall occur on the expected timelines andthat regulatory authorities will provide clearance for trials to be initiated on the expected timelines or at all; anduncertainties as to whether the Company’s cash resources are sufficient to fund its foreseeable and unforeseeableoperating expenses and capital expenditure requirements for the period anticipated. These and other risks aredescribed in greater detail under the caption “Risk Factors” included in the Company’s most recent Annual Reporton Form 10-K, which is on file with the Securities and Exchange Commission, as updated by the Company’ssubsequent filings with the Securities and Exchange Commission, and in other filings that the Company may makewith the Securities and Exchange Commission in the future. Any forward-looking statements contained in thispress release represent the Company’s views only as of the date hereof and should not be relied upon asrepresenting its views as of any subsequent date. Except as required by law, the Company explicitly disclaims anyobligation to update any forward-looking statements. This press release contains hyperlinks to information that is not deemed to be incorporated by reference in thispress release.
Page 4
EDITAS MEDICINE, INC. Consolidated Statement of Operations (amounts in thousands, except share and per share data) (Unaudited) Three Months EndedJune 30, Six Months EndedJune 30, 2026 2025 2026 2025 Collaboration and other research and developmentrevenues $ 11,890 $ 3,578 $ 14,721 $ 8,236 Operating expenses: Research and development 20,180 16,181 37,780 42,774 General and administrative 11,603 12,859 21,837 26,234 Restructuring and impairment charges (1,339) 26,082 (1,339) 66,935 Total operating expenses 30,444 55,122 58,278 135,943 Operating loss (18,554) (51,544) (43,557) (127,707) Other income (expense), net: Interest expense related to sale of future revenues (1,061) (2,020) (2,133) (4,236) Interest income, net 1,368 2,087 2,574 4,803 Other income (expense), net 17 (1,758) (96) (2,183) Total other income (expense), net 324 (1,691) 345 (1,616) Net loss $ (18,230) $ (53,235) $ (43,212) $ (129,323) Net loss per share, basic and diluted $ (0.15) $ (0.63) $ (0.40) $ (1.54) Weighted-average common shares outstanding, basic anddiluted 119,294,615 84,412,200 108,646,137 83,737,382
Page 5
EDITAS MEDICINE, INC. Selected Consolidated Balance Sheet Items (amounts in thousands) (Unaudited) June 30, December 31, 2026 2025 Cash and cash equivalents $ 211,645 $ 146,645 Working capital 149,633 117,649 Total assets 237,364 186,534 Deferred revenue, net of current portion 4,000 44,509 Total stockholders' equity 105,281 27,288 ### Investor and Media Contacts: ir@editasmed.commedia@editasmed.com